From the Research
PPAR delta activation is a potential therapeutic target for metabolic disorders, and its agonists have shown promise in improving insulin sensitivity and fatty acid metabolism, as demonstrated by the most recent study in 2019 1. The role of PPAR delta in regulating metabolism, particularly fatty acid oxidation and energy homeostasis, has been extensively studied. It is one of three PPAR subtypes (alpha, gamma, and delta/beta) and is expressed throughout the body, with high levels in skeletal muscle, adipose tissue, and the liver. Some key points about PPAR delta include:
- PPAR delta activation enhances fatty acid metabolism, increases mitochondrial function, and improves insulin sensitivity, as shown in a study published in 2006 2.
- PPAR delta has gained attention as a potential therapeutic target for metabolic disorders like type 2 diabetes, obesity, and dyslipidemia, with some experimental PPAR delta agonists showing promise in preclinical studies, but none are currently approved for clinical use due to safety concerns, including potential cancer risks observed in animal studies.
- Exercise naturally activates PPAR delta, which partly explains the metabolic benefits of regular physical activity.
- A study published in 2019 1 demonstrated that the PPARβ/δ agonist GW501516 inhibits TNFα-induced repression of adiponectin and insulin receptor in 3T3-L1 adipocytes, highlighting the potential of PPAR delta as a therapeutic target for insulin resistance. Overall, the most recent and highest quality study suggests that PPAR delta activation is a promising therapeutic approach for metabolic disorders, particularly insulin resistance and type 2 diabetes, as demonstrated by the study published in 2019 1.